Semax
A synthetic heptapeptide analog of ACTH (4-10) developed in Russia as a nootropic and neuroprotectant, approved there for stroke recovery and cognitive enhancement.
Also known as: MEHFPGP, Semax 1%
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
Semax is derived from the ACTH fragment 4-10 with an added Pro-Gly-Pro tail for enzymatic stability. It increases BDNF, NGF, and TrkB expression in the brain, promoting neuronal survival and synaptic plasticity. It modulates dopaminergic and serotonergic systems and has anti-inflammatory effects through downregulation of pro-inflammatory cytokines. Unlike full-length ACTH, it does not stimulate the adrenal cortex or affect cortisol levels.
Common Applications
Safety & Considerations
Excellent safety profile reported in Russian clinical trials. Administered intranasally. No hormonal side effects (no cortisol stimulation despite ACTH backbone). No sedation, tolerance, or withdrawal reported. Limited data from Western clinical trials. May theoretically interact with dopaminergic medications. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.